Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

19-10-2020 | EMA | News

approvalsWatch

Olaparib recommended for BRCA-mutated metastatic CRPC

Author: Lynda Williams

print
PRINT
insite
SEARCH

medwireNews: Olaparib has been granted a positive opinion by the EMA for use in patients with metastatic castration-resistant prostate cancer (CRPC) with a somatic or germline BRCA1 or BRCA mutation.

The Committee for Medicinal Products for Human Use recommends marketing authorization for the PARP inhibitor after disease progression on treatment that has included a new hormonal agent.

The announcement follows the US FDA’s decision to approve both olaparib and rucaparib in a similar indication.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

print
PRINT
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Related content

10-10-2019 | Castration-resistant prostate cancer | Highlight | News

PROfound paves the way for precision medicine in mCRPC
Image Credits